Petersen Greg
Petersen Greg's purchase track record
Petersen Greg has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/11/2024 | CNSY | $17K | pending | pending | — |
| 5/8/2024 | CNSY | $25K | pending | pending | — |
| 9/11/2023 | CNSY | $34K | pending | pending | — |
| 5/17/2022 | CNSY | $17K | pending | pending | — |
| 10/27/2021 | CNSY | $22K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ATER Included in 12 Consumer Discretionary Stocks Moving After-Market. Aterian Inc. (ATER) was among 12 consumer discretionary stocks that moved during Wednesday’s after‑market session. The after‑market activity can signal investor sentiment ahead of the next day’s opening. ATER’s move came while its RSI was near neutral, suggesting no strong overbought or oversold pressure at that time.
Transaction History
| CNSY | ▲ Buy | Open Market | 12,500 | $17K | 9/11/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 12,255 | $25K | 5/8/2024 | View on chart |
| CNSY | ▲ Buy | Open Market | 20,000 | $34K | 9/11/2023 | View on chart |
| CNSY | ▲ Buy | Open Market | 30,000 | $17K | 5/17/2022 | View on chart |
| CNSY | ▲ Buy | Open Market | 12,500 | $22K | 10/27/2021 | View on chart |
| ATER | ▲ Buy | Grant | 8,449 | $0 | 9/30/2021 | View on chart |
| ATER | ▲ Buy | Grant | 1,281 | $0 | 9/30/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Cerenome projects $1.55M in Q3 CNSide billings
Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.
Cerenome projects $1.55M in Q3 CNSide billings. Cerenome expects $1.55 million in gross billings for its CNSide platform in the third quarter. The company also announced it will hold a business update call on September 30, 2026, to discuss progress in its diagnostic division. This update provides specific revenue expectations for the company's main product line.